Type two diabetes mellitus and microvascular complications in patients with coronary artery disease: prevalence, prognosis and choice of antithrombotic therapy

Козиолова, Н. А.; Polyanskaya, E. A.; Mironova, S. V.

doi:10.21886/2712-8156-2022-3-4-7-24

Cited by 2 publications

(1 citation statement)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Эти данные подтверждают ряд научных исследований во всем мире [2,3]. Смертность от ССЗ при СД регистрируется в 38,6% у пациентов с СД 1 типа и в 38,6% при СД 2 типа [1,4].…”

Section: Introductionunclassified

Cardiometabolic risk factors in patients with type 2 diabetes and sarcopenia

Samoilova,

Matveeva,

Khoroshunova

et al. 2023

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To analyze risk factors for sarcopenia in atherosclerosis involvement of target organs in patients with type 2 diabetes (T2D).Material and methods. The study included 84 patients with T2D, divided into groups according to the 2019 criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2). All patients were surveyed using a 36-item short-form health survey (SF-36), Sarcopenia and Quality of Life (SarQoL), Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F), grip test, 4-meter walk test, bioelectrical impedance analysis, 24-hour blood pressure monitoring and cardiac ultrasound. Differences were considered significant at p<0,05.Results. Patients with sarcopenia have lower levels of fat, muscle, cell mass, appendicular mass index, fluid, protein, and minerals. In the group with sarcopenia, higher levels of total cholesterol, low-density lipoprotein cholesterol, glycated hemoglobin, and hypocalcemia were detected. Triglyceride levels were high in those with presarcopenia. In the same group, unstable blood pressure, increased myocardial mass and severe lower limb atherosclerosis were recorded.Conclusion. Sarcopenia is one of the important medical and social problems and is accompanied by unfavorable outcomes. The combination of sarcopenia and T2D can contribute to the rapid development of macro- and microangiopathy and increase the cardiovascular risk.

show abstract

Section: Introductionunclassified

Cardiometabolic risk factors in patients with type 2 diabetes and sarcopenia

Samoilova,

Matveeva,

Khoroshunova

et al. 2023

Cardiovasc Ther Prev

View full text Add to dashboard Cite

show abstract

The effect of a medicinal plant preparation on the frequency of episodes of exacerbation of recurrent cystitis and metabolic parameters in patients with type 2 diabetes mellitus taking glyphlosins

Tsygankova,

Evdokimova,

Timoshchenko

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Background. The problem of recurrent urinary tract infections (UTI) in patients with type 2 diabetes mellitus (DM 2) is relevant, especially when there is a combination of predisposing factors, such as female gender, history of UTI episodes, and therapy with sodium glucose cotransporter type 2 (SGLT-2) inhibitors, and the choice of effective and safe means could cause some difficulties, including ina terms of the burden of antibiotic resistance. Aim. To evaluate the effectiveness and safety of the phytoproduct Canephron N for the prevention of exacerbations of recurrent cystitis and the effect on metabolic parameters in patients with type 2 diabetes taking SGLT-2 inhibitors. Materials and methods. Prospective, randomized, open, parallel group study in 60 women. The main group took the drug Canephron N for 3 months. The main parameters for evaluating were the frequency of recurrence of cystitis, level of albuminuria and LDL-cholesterol peroxidation product malondialdehyde. Results. Within 3 months of taking Canephron N, exacerbations of chronic cystitis were diagnosed 2 times less often, a decrease in albuminuria was found in the form of an increase in the proportion of patients with an optimal level of albuminuria by 20%, a 50% reduction in the frequency of the initial increase in albuminuria, and the absence of moderate albuminuria in all patients at the end of course of therapy. A decrease in the level of MDA by 1.4 times was noted (p=0.019). Conclusion. Thus, the herbal drug Canephron N can be used for accompanying therapy and prophylactic treatment in patients with recurrent cystitis on the background of DM 2, taking SGLT-2 inhibitors. The course of therapy should last at least 3 months.

show abstract

Type two diabetes mellitus and microvascular complications in patients with coronary artery disease: prevalence, prognosis and choice of antithrombotic therapy

Cited by 2 publications

References 83 publications

Cardiometabolic risk factors in patients with type 2 diabetes and sarcopenia

Cardiometabolic risk factors in patients with type 2 diabetes and sarcopenia

The effect of a medicinal plant preparation on the frequency of episodes of exacerbation of recurrent cystitis and metabolic parameters in patients with type 2 diabetes mellitus taking glyphlosins

Contact Info

Product

Resources

About